Akari Therapeutics (AKTX) Cash from Operations (2014 - 2026)

Akari Therapeutics has disclosed Cash from Operations across 9 years of filings, most recently posting 2488000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 2488000.0, down 15.72% year-over-year; the trailing twelve-month figure through Mar 2026 was 10906000.0 (down 2.33% YoY), and the FY2025 annual result was 10568000.0, up 15.81% from the prior year.
• Cash from Operations came in at 2488000.0 for Q1 2026 at Akari Therapeutics, up from 3041000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 1490000.0 in Q3 2024 to a low of 4894000.0 in Q2 2024.
• The 4-year median for Cash from Operations is 3041000.0 (2025), against an average of 3233846.15.
• Across the five-year window, Cash from Operations jumped 51.83% in 2024 and slumped 43.17% in 2025, its largest moves.
• Akari Therapeutics' Cash from Operations stood at 4409000.0 in 2023, then surged by 51.83% to 2124000.0 in 2024, then plunged by 43.17% to 3041000.0 in 2025, then grew by 18.18% to 2488000.0 in 2026.
• The last three Cash from Operations figures came in at 2488000.0 (Q1 2026), 3041000.0 (Q4 2025), and 2121000.0 (Q3 2025), per Business Quant data.